Sinopharm Tech Holdings Limited (Sinopharm Tech) has resubmitted its Monthly Return for Equity Issuer for the period ended 28 February 2026, confirming that its authorised, registered and issued share capital remained unchanged during the month.

Authorised Capital • The company’s authorised share capital stayed at HKD 200.00 million, divided into 12.80 billion ordinary shares and 3.20 billion non-voting convertible preference shares, each with a par value of HKD 0.0125. • The present structure reflects a capital reorganisation approved in August 2024 and effective since November 2024.

Issued Shares and Public Float • Issued ordinary shares were steady at 633.69 million, with no treasury shares held. • Public shareholders owned 24.98 % of the issued ordinary shares, satisfying Hong Kong Stock Exchange free-float requirements. • The company reported 1.48 billion convertible preference shares outstanding, also unchanged during the month.

Equity Instruments and Potential Dilution • Share options under the 2021 Share Option Scheme declined marginally as 0.20 million options lapsed, leaving 5.08 million options outstanding. No new shares were issued from option exercises, and no funds were raised. • The outstanding convertible preference shares, issued in November 2024 through loan capitalisation agreements, total HKD 148.02 million in nominal value. They are convertible into ordinary shares at a one-for-one ratio at an exercise price of HKD 0.10 and carry a ten-year conversion window. • No warrants, other convertible instruments, or additional share issuance agreements were executed during the month.

Liquidity and Compliance • The filing confirms that all regulatory and listing rule conditions have been met and that the company received full consideration for any previously issued securities. • No share repurchases, redemptions, or treasury share movements occurred in February 2026.

Overall, Sinopharm Tech’s February statement highlights a period of capital stability, the maintenance of a compliant public float, and minimal dilution risk in the near term.